FDA Approves Gefurulimab for Generalized Myasthenia Gravis
Federal regulators have approved a new injectable nanobody, gefurulimab, for adults with anti-AChR antibody-positive generalized myasthenia gravis following positive phase III trial results.
❤️Conditions & CarePhoto: medpagetoday.com
Key points
- FDA approved gefurulimab for generalized myasthenia gravis in adults with specific antibodies.
- The phase III PREVAIL trial showed significant improvements in daily living activity scores versus placebo.
- The drug carries a boxed warning for serious meningococcal infections and requires a REMS program.
The U.S. Food and Drug Administration has granted approval to gefurulimab, marketed as Klygefa, as a treatment for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. The therapy functions as a dual-binding nanobody designed to block the activation of complement component 5.
Clinical Trial Findings
The regulatory decision follows the phase III PREVAIL study, which evaluated 260 participants randomized to receive either weekly subcutaneous injections of the drug or a placebo over a 26-week period. According to the data, the trial achieved its primary endpoint by demonstrating a statistically significant improvement in scores on the Myasthenia Gravis Activities of Daily Living scale compared with the placebo group at week 28. Researchers noted that functional improvements began as early as the first week of treatment and persisted throughout the study.
Key secondary endpoints, including Quantitative Myasthenia Gravis scores, also reflected favorable changes by week four. The therapy's design allows for once-weekly dosing by binding to serum albumin to extend its half-life. Open-label extension data further indicated that these functional benefits were maintained through 52 weeks.
Safety and Precautions
Regarding safety, the incidence of treatment-emergent adverse events was comparable between the therapy and placebo arms, with most incidents categorized as mild to moderate. The most frequently reported adverse events among patients receiving the drug included injection site reactions, headaches, and back pain. Serious adverse events occurred in 12 individuals, alongside a single death deemed unrelated to the treatment.
Because of safety considerations, the medication is subject to a risk evaluation and mitigation strategy program and carries a boxed warning regarding severe and life-threatening infections caused by Neisseria meningitidis. Patients are advised to follow all guidelines regarding meningococcal vaccinations. Always consult a qualified healthcare provider for personalized medical advice and treatment decisions.
- What to know: Gefurulimab is a once-weekly subcutaneous treatment for specific adults with generalized myasthenia gravis.
- Trial data: The approval is backed by the phase III PREVAIL trial showing sustained functional improvements.
- Safety warning: The medication carries a boxed warning for serious meningococcal infections and requires appropriate vaccination.
Source medpagetoday.com — medpagetoday.com/neurology/generalneurology/123885 ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…